About ATP-dependent Clp protease proteolytic subunit, mitochondrial
ATP-dependent Clp protease proteolytic subunit, mitochondrial (CLPP) is a protein
from Homo sapiens identified by UniProt accession
Q16740, 277 residues long.
MolForge cross-references it against 0 known binders and
168 disease associations.
Target properties
| Protein name | ATP-dependent Clp protease proteolytic subunit, mitochondrial |
|---|
| UniProt accession | Q16740 |
|---|
| Gene | CLPP |
|---|
| Organism | Homo sapiens |
|---|
| Length | 277 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (168)
Diseases linked to this target (Open Targets).
- Perrault syndrome · score 0.77
- Perrault syndrome 1 · score 0.45
- Perrault syndrome 2 · score 0.37
- genetic disorder · score 0.19
- cancer · score 0.09
- breast cancer · score 0.08
- hepatocellular carcinoma · score 0.08
- triple-negative breast cancer · score 0.05
- neoplasm · score 0.05
- ring chromosome Y · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q16740-F1 | alphafold | PREDICTED | 82.28 | — |
Amino-acid sequence (277 residues)
MWPGILVGGA RVASCRYPAL GPRLAAHFPA QRPPQRTLQN GLALQRCLHA TATRALPLIP IVVEQTGRGE RAYDIYSRLL RERIVCVMGP IDDSVASLVI AQLLFLQSES NKKPIHMYIN SPGGVVTAGL AIYDTMQYIL NPICTWCVGQ AASMGSLLLA AGTPGMRHSL PNSRIMIHQP SGGARGQATD IAIQAEEIMK LKKQLYNIYA KHTKQSLQVI ESAMERDRYM SPMEAQEFGI LDKVLVHPPQ DGEDEPTLVQ KEPVEAAPAA EPVPAST
Explore ATP-dependent Clp protease proteolytic subunit, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets